drugset / Trial / NCT02533323
P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens
NaSingle-groupOpen-labelTreatment
Summary
This prospective study was conducted to evaluate the efficacy and safety profiles of first-line combined gemcitabine, oxaliplatin, and Pegaspargase (P-Gemox) in newly diagnosed, nasal type, extranodal natural killer/T-cell lymphoma.
Timeline
- Start
- 2012-01
- Primary completion
- 2016-09
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |
| Subject | Pegaspargase | Protein / enzyme biologic | 2500 unknown | Intramuscular |